CLARIO HOLDINGS
Acquired by
THERMO FISHER SCIENTIFIC
CLARIO HOLDINGS acquired by THERMO FISHER SCIENTIFIC
Target
CLARIO HOLDINGS
Acquirer
THERMO FISHER SCIENTIFIC
Context
Thermo Fisher Scientific has finalized the acquisition of Clario Holdings, Inc. from a prominent shareholder consortium led by Astorg, Nordic Capital, Novo Holdings, and Cinven. The strategic rationale for this transaction centers on the deep integration of the target's industry-leading endpoint data platform into the group's Laboratory Products and Biopharma Services segment. This fusion effectively creates a specialized powerhouse in clinical research, allowing the organization to offer a unified, digital-first infrastructure for capturing and validating clinical evidence from molecule to market. By pairing sophisticated data intelligence with its existing clinical research organization services, the buyer can now deliver unrivaled insights into therapeutic safety and effectiveness.
CLARIO HOLDINGS, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Clario operates as a premier technology organization dedicated to providing high-fidelity endpoint data solutions for the global clinical trial landscape. The entity’s business model is centered on a proprietary digital platform that integrates patient data from diverse sources, including medical devices, clinical sites, and direct patient reporting. Its value proposition is anchored in technical operational depth, ensuring that pharmaceutical and biotech sponsors can collect, manage, and analyze complex clinical evidence across all phases of drug development. Strategically, the firm focuses on the digital modernization of clinical trials, providing the critical data infrastructure required for regulatory approval and pharmaceutical innovation. By maintaining a specialized focus on the convergence of technology and clinical science, the organization ensures a mission-critical role in the structural efficiency of novel therapy commercialization. The entity prioritizes data integrity and industrialized analytical standards to facilitate the structural advancement of patient health outcomes.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with CLARIO HOLDINGS
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.